EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Oncolytic Virus VV-GMCSF-Lact Against Immunocompetent Glioma

Alisa Ageenko iD, Natalia Vasileva iD, Gaukhar Yusubalieva iD, Aleksandra Sen'kova iD, Alexander Romashchenko iD, Ilya Gubskiy iD, Fedor Zabozlaev, Evgeniy Zavyalov, Maya Dymova iD, Vladimir Richter, Elena Kuligina iD

Cells · 2025

DOI: 10.3390/cells14201619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Alisa Ageenko und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Biology and Fundamental Medicine Siberian Branch of the Russian Academy of Sciences, Akad. Lavrentiev Ave, 8, Novosibirsk 63009…. Hauptthemen laut MEDLINE: Glioma, Oncolytic Virotherapy, Oncolytic Viruses, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, Russian state-funded project for ICBFM SB RAS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Virotherapy is a promising method for treating oncological diseases, including such aggressive and difficult-to-treat brain tumors such as glioblastoma. Recombinant vaccinia virus VV-GMCSF-Lact has previously shown high antitumor potential against tumor cells of varying histogenesis, including gliomas, and completed a Phase I clinical trial, demonstrating safety and good tolerability in patients with recurrent/refractory metastatic breast cancer. Investigating two types of VV-GMCSF-Lact delivery, intravenous and intratumoral, into orthotopically transplanted C6 glioma in rats, it was shown that intratumoral injection significantly increases tumor volumes in comparison with intravenous virus delivery and is accompanied by noticeable toxic effects. Extensive areas of necrotic decay of tumor tissue and its significant mixed-cell infiltration and peritumoral edema, affecting the tumor volume, were detected using H&E staining of C6 tumors after intratumoral injection of VV-GMCSF-Lact. However, only with intratumoral administration was a significant decrease in the level of the tumor cell proliferation marker Ki67 demonstrated by immunohistochemical staining. The observed toxic effects of VV-GMCSF-Lact with intratumoral administration revealed the need for dose selection, which was performed on a mouse GL261 glioma model. Results of the study allowed us to determine the viral dose that does not lead to toxic effects and can potentially increase life expectancy of mice. The data obtained show the need for careful selection of both the route of viral drug dose and administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaOncolytic VirotherapyOncolytic VirusesBrain NeoplasmsGranulocyte-Macrophage Colony-Stimulating FactorVaccinia virusImmunocompetenceAnimalsRatsCell Line, TumorMiceFemaleHumans

Stichwörter der Autor:innen

C6 gliomaGL261 gliomaoncolytic virus deliveryvirotherapy

Substanzen

Granulocyte-Macrophage Colony-Stimulating Factor

Autor:innen und Institutionen

  • Institute of Chemical Biology and Fundamental Medicine Siberian Branch of the Russian Academy of Sciences, Akad. Lavrentiev Ave, 8, Novosibirsk 630090, Russia.
  • LLC "Oncostar", Inzhenernaya Str 23, Novosibirsk 630090, Russia.
  • Federal Research and Clinical Center of the Federal Medical and Biological Agency of Russia, Malaya Pirogovskaya Str 1a, Moscow 119435, Russia.
  • Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Akad. Lavrentiev Ave, 10, Novosibirsk 630090, Russia.
  • Department of Medical Nanobiotechnology, Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Ostrovityanova Str 1, Moscow 117997, Russia.
  • Federal Center of Brain Research and Neurotechnologies, Federal Medical Biological Agency of Russia, Ostrovityanova Str 1, Moscow 117513, Russia.

ORCID-Profile: Alisa Ageenko, Natalia Vasileva, Gaukhar Yusubalieva, Aleksandra Sen'kova, Alexander Romashchenko, Ilya Gubskiy, Maya Dymova, Elena Kuligina

Förderung

  • Russian Science Foundation
  • Russian state-funded project for ICBFM SB RAS

Zitieren

APA

Ageenko, A., Vasileva, N., Yusubalieva, G., Sen'kova, A., Romashchenko, A., Gubskiy, I., Zabozlaev, F., Zavyalov, E., Dymova, M., Richter, V., & Kuligina, E. (2025). Efficacy of Oncolytic Virus VV-GMCSF-Lact Against Immunocompetent Glioma. Cells. https://doi.org/10.3390/cells14201619

Vancouver

Ageenko A, Vasileva N, Yusubalieva G, Sen'kova A, Romashchenko A, Gubskiy I, et al. Efficacy of Oncolytic Virus VV-GMCSF-Lact Against Immunocompetent Glioma. Cells. 2025. doi:10.3390/cells14201619

BibTeX
@article{Ageenko2025,
  author = {Ageenko, Alisa and Vasileva, Natalia and Yusubalieva, Gaukhar and Sen'kova, Aleksandra and Romashchenko, Alexander and Gubskiy, Ilya and Zabozlaev, Fedor and Zavyalov, Evgeniy and Dymova, Maya and Richter, Vladimir and Kuligina, Elena},
  title = {Efficacy of Oncolytic Virus VV-GMCSF-Lact Against Immunocompetent Glioma},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14201619}
}
Kostenlos starten →